Autolus Therapeutics stock rose 8.1% on Monday. This happened after Needham analyst Gil Blum raised his price target from $10 to $11 and kept a Buy rating.
Blum highlighted the strong first-year launch of Aucatzyl, which made about $76 million in sales. He also added Autolus to Needham’s conviction list, replacing Taysha Gene Therapies.
Even with strong sales, investors are still cautious about Autolus, especially about when it will become profitable. Blum expects the company to break even by 2028 based just on Aucatzyl sales.
Blum said several upcoming developments could boost growth. These include results from the FELIX study and obe-cel trials in pediatric acute lymphoblastic leukemia. The potential use of obe-cel for lupus nephritis, with updates expected in early 2026, is also seen as underappreciated by the market.
The analyst noted that Autolus has a solid financial position, expecting around $370 million by the end of 2025. This gives the company enough resources to grow its commercial operations.
